CDKN2A and oropharynx cancer: Following primary therapy, all the patients’ specimens were reported to be ctDNA-negative, and HPV-derived ctDNA was found at the stage of relapse, implying that HPV-derived ctDNAs can be used as a putative marker for detecting oropharyngeal cancer (p16-positive) relapse.